PARMAR KUSH (CIK 1664281) reported 14 SEC Form 4 insider transactions across 3 companies over the past 18 months (most recent 2025-11-18). Recent activity: Sell TRDA (200,000 shares), Buy CAMP (2.9M shares), Sell SKYE (58,642 shares), Sell SKYE (2,314 shares), Sell SKYE (163,979 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-18 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 200,000 | $1.8M |
| 2025-09-15 | Camp4 Therapeutics Corp (CAMP) | Insider | Buy | 2.9M | $4.5M |
| 2025-08-22 | Skye Bioscience, Inc. (SKYE) | Insider | Sell | 58,642 | $209,352 |
| 2025-08-22 | Skye Bioscience, Inc. (SKYE) | Insider | Sell | 2,314 | $8,261 |
| 2025-08-22 | Skye Bioscience, Inc. (SKYE) | Insider | Sell | 163,979 | $560,808 |
| 2025-08-22 | Skye Bioscience, Inc. (SKYE) | Insider | Sell | 6,470 | $22,127 |
| 2025-07-11 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 20,065 | $150,488 |
| 2025-07-11 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 6,935 | $52,012 |
| 2025-07-01 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 55,735 | $385,129 |
| 2025-07-01 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 19,265 | $133,121 |
| 2025-07-01 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 18,578 | $126,516 |
| 2025-07-01 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 6,422 | $43,734 |
| 2025-07-01 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 18,578 | $132,275 |
| 2025-07-01 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 6,422 | $45,725 |
Source: SEC Form 4 filings · as of 2025-11-18